Literature DB >> 17913972

Hypertonic saline for hyponatremia: risk of inadvertent overcorrection.

Hashim K Mohmand1, Dany Issa, Zubair Ahmad, Joseph D Cappuccio, Ruth W Kouides, Richard H Sterns.   

Abstract

BACKGROUND AND OBJECTIVES: Data regarding dosage-response relationships for using hypertonic saline in treatment of hyponatremia are extremely limited. Objectives of this study were to assess adherence to previously published guidelines (limiting correction to <12 mEq/L per d and <18 mEq/L per 48 h) in treating hyponatremia with hypertonic saline and to determine the predictive accuracy of the Adrogué-Madias formula. DESIGN, SETTING, PARTICIPANTS &amp; MEASUREMENTS: A retrospective review was conducted of all 62 adult, hyponatremic patients who were treated with hypertonic saline during 5 yr at a 528-bed, acute care, teaching hospital.
RESULTS: Median infusion rate was 0.38 ml/kg per h, increasing serum sodium concentration by 0.47 +/- 0.05 mEq/L per h, 7.1 +/- 0.6 mEq/L per 24 h, and 11.3 +/- 0.7 mEq/L per 48 h. In 11.3% of cases, the increase was >12 mEq/L per 24 h and in 9.7% was >18 mEq/L per 48 h. No patient's rate was corrected by >25 mEq/L per 48 h. Among patients with serum sodium <120 mEq/L, the observed increase in sodium exceeded the rise predicted by the Adrogué-Madias formula in 74.2%; the average correction in overcorrectors was 2.4 times the predicted. Inadvertent overcorrection was due to documented water diuresis in 40% of cases.
CONCLUSIONS: The Adrogué-Madias formula underestimates increase in sodium concentration after hypertonic saline therapy. Unrecognized hypovolemia and other reversible causes of water retention pose a risk for inadvertent overcorrection. Hypertonic saline should be infused at rates lower than those predicted by formulas with close monitoring of serum sodium and urine output.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913972     DOI: 10.2215/CJN.00910207

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  50 in total

1.  Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia.

Authors:  Haruyuki Suzuki; Yoshihisa Sugimura; Shintaro Iwama; Hiromi Suzuki; Ozaki Nobuaki; Hiroshi Nagasaki; Hiroshi Arima; Makoto Sawada; Yutaka Oiso
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

2.  The association between sodium fluctuations and mortality in surgical patients requiring intensive care.

Authors:  Dominic C Marshall; Justin D Salciccioli; Ross J Goodson; Marco A Pimentel; Kristi Y Sun; Leo Anthony Celi; Joseph Shalhoub
Journal:  J Crit Care       Date:  2017-02-13       Impact factor: 3.425

3.  Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.

Authors:  Jason D Woodfine; Manish M Sood; Thomas E MacMillan; Rodrigo B Cavalcanti; Carl van Walraven
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-12       Impact factor: 8.237

Review 4.  Treatment of Severe Hyponatremia.

Authors:  Richard H Sterns
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-02       Impact factor: 8.237

5.  Clinical management of SIADH.

Authors:  Peter Gross
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

6.  Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.

Authors:  Rick P Vaghasiya; Maria V DeVita; Michael F Michelis
Journal:  Int Urol Nephrol       Date:  2011-05-24       Impact factor: 2.370

7.  Management of hyponatremia in various clinical situations.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

8.  Current and future treatment options in SIADH.

Authors:  Robert Zietse; Nils van der Lubbe; Ewout J Hoorn
Journal:  NDT Plus       Date:  2009-11

9.  DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.

Authors:  Anjana Perianayagam; Richard H Sterns; Stephen M Silver; Marvin Grieff; Robert Mayo; John Hix; Ruth Kouides
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

Review 10.  New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children.

Authors:  Michael L Moritz; Juan Carlos Ayus
Journal:  Pediatr Nephrol       Date:  2009-11-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.